SpringWorks Therapeutics has been granted a patent for a method of treating melanoma using a pharmaceutical composition containing a specific crystalline form of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. The method involves administering 1 mg to 4 mg of the compound to patients in need. GlobalData’s report on SpringWorks Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights SpringWorks Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on SpringWorks Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. SpringWorks Therapeutics's grant share as of January 2024 was 6%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of melanoma using specific pharmaceutical composition

Source: United States Patent and Trademark Office (USPTO). Credit: SpringWorks Therapeutics Inc

A recently granted patent (Publication Number: US11884610B2) discloses a method for treating melanoma in patients by administering a pharmaceutical composition containing a specific compound. The method involves administering 1 mg to 4 mg of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, which can be in a crystalline form or an amorphous solid. The compound is represented by Formula (I) and is delivered in a pharmaceutically acceptable carrier.

Furthermore, the patent outlines different variations of the pharmaceutical composition, ranging from 1 mg to 4 mg of the specified compound. The method allows for flexibility in dosing, with options for administering 1 mg, 2 mg, 3 mg, or 4 mg of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. This approach provides healthcare professionals with a range of dosing options to tailor the treatment to individual patient needs, potentially improving efficacy and minimizing adverse effects in the treatment of melanoma.

To know more about GlobalData’s detailed insights on SpringWorks Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies